Impact of the Arrival on the French Market of New First Line Oral Treatments on the Delay Between MS Onset and First Disease Modifying Treatment (DMTs) Administration

NCT03308994 · clinicaltrials.gov ↗

COMPLETED

Status

650

Enrollment

OTHER

Sponsor class

Conditions

C10.114.375.500

Interventions

OTHER: Delay between MS onset and introduction of first line DMT
OTHER: EDI

Sponsor

University Hospital, Caen

Collaborators

[object Object]
[object Object]